# Innoviva (INVA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INVA
## Company Profile
- Ticker: INVA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Small Molecule Drugs
## Stock Data
- Close: 20.81 USD
- Market cap: 1575816791.15 USD
- Last updated: 2026-08-12
## Business Overview
### Diversified Biopharmaceutical Model
Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies.
### Respiratory Royalties
The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support investment in additional healthcare assets.
### Innoviva Specialty Therapeutics
The IST portfolio includes GIAPREZA for distributive shock, XACDURO for hospital-acquired bacterial pneumonia, XERAVA for complicated intra-abdominal infections and ZEVTERA, an advanced-generation cephalosporin.
### NUZOLVENCE
NUZOLVENCE is an oral antibiotic approved for uncomplicated urogenital gonorrhea in adults and eligible adolescents, adding a differentiated infectious-disease product to IST.
## Why The Stock Is Moving

The latest company update was “Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award”. INVA changed 0.29% and closed at $20.81 on Aug 12, 2026, indicating a relatively limited closing-price reaction to this company update.

## Future Catalysts

- U.S. commercial availability of NUZOLVENCE in the second half of 2026.

## Recent News
- 2026-08-11 20:05 EST — [Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award](https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-antimicrobial-therapies-xacduro-zevtera-and-nuzo-b6c9dc31) — Source: Innoviva
- 2026-08-05 20:05 EST — [Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress](https://biopharmsignal.com/news/INVA/innoviva-reports-second-quarter-2026-financial-results-highlights-recent-company-2006edc4) — Source: Innoviva
- 2026-06-18 12:00 EST — [Nortiva Bio Launches to Develop Long-Acting Oral Medicines](https://biopharmsignal.com/news/INVA/nortiva-bio-launches-to-develop-long-acting-oral-medicines-fa8b8b55) — Source: Innoviva
- 2026-06-16 12:00 EST — [Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets](https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-distribution-and-licensing-agreement-w-72aeec01) — Source: Innoviva
- 2026-06-01 15:00 EST — [Innoviva to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-upcoming-investor-conferences-24a49e78) — Source: Innoviva